Kailera Therapeutics, Inc. (NASDAQ:KLRA - Get Free Report) shares traded up 8.6% during mid-day trading on Tuesday . The stock traded as high as $18.19 and last traded at $17.96. 757,067 shares traded hands during trading, an increase of 5% from the average daily volume of 717,646 shares. The stock had previously closed at $16.54.
Wall Street Analyst Weigh In
KLRA has been the topic of several recent research reports. Wall Street Zen downgraded shares of Kailera Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, May 30th. JPMorgan Chase & Co. started coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They issued an "overweight" rating and a $30.00 price target for the company. Leerink Partners assumed coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They set an "outperform" rating and a $36.00 price objective for the company. Weiss Ratings initiated coverage on shares of Kailera Therapeutics in a report on Friday, August 14th. They issued a "sell (d)" rating for the company. Finally, TD Cowen started coverage on Kailera Therapeutics in a research note on Tuesday, May 12th. They set a "buy" rating and a $57.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Kailera Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $42.75.
Check Out Our Latest Research Report on KLRA
Kailera Therapeutics Stock Performance
The company has a 50-day simple moving average of $19.22. The stock has a market capitalization of $2.31 billion and a price-to-earnings ratio of -0.00.
Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($1.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.35). As a group, sell-side analysts expect that Kailera Therapeutics, Inc. will post -3.89 EPS for the current year.
Hedge Funds Weigh In On Kailera Therapeutics
Several institutional investors have recently bought and sold shares of the business. California State Teachers Retirement System bought a new position in Kailera Therapeutics in the second quarter worth approximately $309,000. Frazier Life Sciences Management L.P. purchased a new stake in shares of Kailera Therapeutics during the 2nd quarter worth $24,233,000. Atlas Venture Life Science Advisors LLC purchased a new stake in shares of Kailera Therapeutics during the 2nd quarter worth $113,923,000. Finally, Wellington Management Group LLP bought a new stake in Kailera Therapeutics during the second quarter valued at about $64,308,000.
About Kailera Therapeutics
(
Get Free Report)
We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Kailera Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kailera Therapeutics wasn't on the list.
While Kailera Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
